[14] Xultophy (insulin degludec/liraglutide) [prescribing information]
Liraglutida: La liraglutida, tambin desarrollada por Novo Nordisk, fue uno de los primeros agonistas GLP-1 aprobados para diabetes tipo 2 y, ms tarde, para el tratamiento de la obesidad
Neuroscientific research has further examined the peptides interaction with monoaminergic pathways, particularly those involving dopamine and serotonin signaling
GLP-1 drugs are being "increasingly used" among women who've just had a baby, a research letter published on Nov
Oxidized Prdx2 forms an interchain disulfide, which is recycled by thioredoxin and thioredoxin reductase, and this requires reducing equivalents from NADPH
This work was supported by a grant-in-aid for Scientific Research from the Ministry of Education, Science and Culture of Japan and a grant-in-aid from the Research and Development Program for New Bio-industry Initiatives